Back to Search Start Over

The Novel Finding of Dynamic Change in eGFR Up to One Year after End of Treatment in HCV-Infected Patients Receiving Sofosbuvir and Velpatasvir.

Authors :
Wu, Cheng-Kun
Chen, Li-Wei
Chang, Te-Sheng
Tung, Shui-Yi
Lin, Chun-Yen
Hung, Chao-Hung
Lu, Sheng-Nan
Lin, Chih-Lang
Chen, Chien-Hung
Hsu, Chao-Wei
Hu, Tsung-Hui
Sheen, I-Shyan
Source :
Viruses (1999-4915). Feb2022, Vol. 14 Issue 2, p362. 1p.
Publication Year :
2022

Abstract

Background: The results of long-term renal evolution in HCV-infected patients using sofosbuvir and velpatasvir (SOF/VEL), with or without ribavirin (RBV), are lacking. Aims: We evaluated the renal safety for HCV-infected patients receiving SOF/VEL. Methods: Between 1 June 2019 and 6 July 2020, we included 594 HCV-infected patients receiving SOF/VEL +/− RBV for 12 weeks in Taiwan. Viral eradication rate (defined by sustained virological response at week 12 post-treatment; SVR12) and changes to renal function were considered. Results: SVR12 was achieved in 99.3% (590/594) upon per-protocol analysis. Patients saw improved hepatobiliary function and fibrosis after the start of SOF/VEL therapy. For renal function, those with baseline estimated glomerular filtration rate (eGFR) ≥ 60 (mL/min/1.73 m2) experienced transient on-treatment reduction in renal function that improved upon ending treatment, but recurrent eGFR degradation during one-year follow-up. The use of RBV (OR = 5.200, 95% CI: 1.983–13.634, p = 0.001) was a significant risk factor at SVR24, while diabetes mellitus (OR = 2.765, 95% CI: 1.104–6.922, p = 0.030) and the use of RBV (OR = 3.143, 95% CI: 1.047–9.435, p = 0.041) were identified as significant risk factors of worsening renal function at SVR48. SOF/VEL did not worsen renal function among those with stage 4–5 chronic kidney disease (CKD) who were not receiving dialysis. Conclusions: A trend of decline in eGFR at 1 year after SOF/VEL treatment was observed among diabetic patients with baseline eGFR ≥ 60 (mL/min/1.73 m2) and concomitant use of RBV. The close monitoring of renal function is warranted. Further study should be conducted in order to weigh the risks and benefit of RBV. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
19994915
Volume :
14
Issue :
2
Database :
Academic Search Index
Journal :
Viruses (1999-4915)
Publication Type :
Academic Journal
Accession number :
155712883
Full Text :
https://doi.org/10.3390/v14020362